Brokerages Set $2.50 Target Price for Akari Therapeutics PLC (AKTX)

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating. Akari Therapeutics’ rating score has improved by 50% in the last three months as a result of various analysts’ upgrades and downgrades.

Analysts have set a 1 year consensus price target of $2.50 for the company and are predicting that the company will post ($1.00) EPS for the current quarter, according to Zacks. Zacks has also assigned Akari Therapeutics an industry rank of 179 out of 265 based on the ratings given to related companies.

A number of analysts have recently commented on the company. Zacks Investment Research cut Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 16th. ValuEngine upgraded Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, November 30th.

A hedge fund recently raised its stake in Akari Therapeutics stock. Hikari Power Ltd increased its position in shares of Akari Therapeutics PLC (NASDAQ:AKTX) by 152.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 151,334 shares of the biopharmaceutical company’s stock after purchasing an additional 91,322 shares during the quarter. Hikari Power Ltd owned approximately 1.28% of Akari Therapeutics worth $929,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 21.04% of the company’s stock.

Akari Therapeutics (AKTX) traded down $0.01 during trading on Monday, hitting $3.59. The stock had a trading volume of 327,400 shares, compared to its average volume of 191,600. The stock has a market capitalization of $54.77, a PE ratio of -1.34 and a beta of -8.64. Akari Therapeutics has a 1-year low of $3.18 and a 1-year high of $22.20.

Akari Therapeutics (NASDAQ:AKTX) last posted its quarterly earnings data on Monday, November 13th. The biopharmaceutical company reported ($0.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.91. equities analysts predict that Akari Therapeutics will post -2 earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

About Akari Therapeutics

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Get a free copy of the Zacks research report on Akari Therapeutics (AKTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply